Skip to main content
WHWK logo

Whitehawk Therapeutics, Inc.

WHWKNASDAQHealthcareBiotechnology

$3.33Today:- (-)1Y +32.65%

As of Oct 27, 2026 close

Market cap
$276.01M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.97$5.50
Volume (live)
-
Avg. volume (3M)
355.78K

Whitehawk Therapeutics (WHWK) Income Statement

Whitehawk Therapeutics reported revenue of $7.14M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 72.5% from $25.98M a year earlier. Whitehawk Therapeutics posted a net loss of $20.60M, compared with a net loss of $63.69M a year earlier. Gross margin was 89.4% and operating margin -1601.1%.

Whitehawk Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Whitehawk Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue7.1525.9824.3515.221.0014.580.7520.16
Cost of Revenue0.763.0251.7434.0019.6715.0111.060.00
Gross Profit6.3922.9621.55-18.781.00-0.43-10.3220.16
Operating Expenses
Research & Development90.9651.0348.9332.6619.6715.0111.0617.85
Selling, General & Administrative29.8236.7544.5540.1818.512.121.8513.44
Operating Expenses120.7990.4293.4843.9038.062.121.8531.29
Operating Income-114.40-67.46-71.93-62.68-37.06-2.55-12.17-11.18
Other Income/Expense
Interest Income6.233.936.402.400.010.040.000.00
Interest Expense0.00-0.15-0.230.230.67-0.820.080.78
Other Income/Expense93.803.776.172.17-72.38-0.93-0.080.78
Income
Income Before Tax-20.60-63.69-65.77-60.51-110.09-3.48-12.25-10.40
Income Tax Expense0.000.000.000.000.000.000.000.78
Net Income-20.60-63.69-65.77-60.51-110.09-3.48-12.26-10.40
Net Income - Continuous Operations-20.60-63.69-65.77-60.51-110.09-3.48-12.26-10.40
Net Income - Discontinued Operations--------
EBITDA-20.52-64.63-71.76-58.80-109.32-2.54-12.16-10.35
EBIT-20.60-64.82-71.93-58.96-109.42-2.55--
Depreciation & Amortization0.080.190.170.160.110.010.010.05
Earnings Per Share
Basic EPS--2.00-2.00-3.00-12.00-2.00-2.00-5.00
Diluted EPS--2.00-2.00-3.00-12.00-2.00-2.00-5.00
Basic Shares Outstanding61.8927.0326.9222.518.922.547.422.26
Diluted Shares Outstanding61.8927.0326.9222.518.922.548.022.26

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Whitehawk Therapeutics Financial Statements

What was Whitehawk Therapeutics's revenue in fiscal 2025?

Whitehawk Therapeutics reported revenue of $7.14M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 72.5% from $25.98M a year earlier.

Is Whitehawk Therapeutics profitable?

No. Whitehawk Therapeutics reported a net loss of $20.60M in fiscal 2025. In fiscal 2024 it lost $63.69M.

What is Whitehawk Therapeutics's operating margin?

Whitehawk Therapeutics's operating income was −$114.40M on revenue of $7.14M in fiscal 2025, an operating margin of -1601.1%, compared with -259.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition